Philippe Camus, M.D.

Dijon, France

Back to drug

The Drug-Induced Respiratory Disease Website

VII.a

‘Cardiotoxicity’

The broad term 'cardiotoxicity' encompasses several entities and patterns of cardiac injury including subclinical change in LVEF or cardiac biomarkers, cardiomyopathy, heart failure, AV heart block, conduction abnormalities, myocarditis, myocardial fibrosis, dysrrhythmias, pericarditis, pericardial effusion, tamponade, syncope, cardiac/cardiopulmonary arrest and/or valvular heart dysfunction or disease. Pulmonary edema and pleural effusion may be the annunciating signs and symptoms of cardiotoxicity (PMID 1403060). Cardiotoxicity is a significant hurdle of novel anticancer agent use including the immune checkpoint inhibitors (PMID 25210198, 25574894, 27732808, 29912044, 29980467, 30433897). Can be life-threatening or fatal (PMID 29980467)

Publications

de la Brassinne Bonardeaux O, Born B, Moonen M, Lancellotti P

Mild Cardiotoxicity and Continued Trastuzumab Treatment in the Context of HER2-Positive Breast Cancer.

Journal of clinical medicine 2023 Oct 24;12; — 2023 Oct 24

Calvillo-Argüelles O, Abdel-Qadir H, Suntheralingam S, Michalowska M, Amir E, Thavendiranathan P

Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer.

The American journal of cardiology 2020 Jan 27;; — 2020 Jan 27

Martinello R, Becco P, Vici P, Airoldi M, Del Mastro L, Garrone O, Barone C, Pizzuti L, D'Alonzo A, Bellini E, Milani A, Bonzano A, Montemurro F

Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity.

The breast journal 2019 May;25;444-449 — 2019 May — 444-449

Mohan N, Jiang J, Dokmanovic M, Wu WJ

Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers.

Antibody therapeutics 2018 Aug 31;1;13-17 — 2018 Aug 31 — 13-17

Mantarro S, Rossi M, Bonifazi M, D'Amico R, Blandizzi C, La Vecchia C, Negri E, Moja L

Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer.

Internal and emergency medicine 2016 Feb;11;123-40 — 2016 Feb — 123-40

Pistilli B, Marcellusi A, Latini L, Accardi R, Ferretti B, Benedetti G

Cardiotoxicity related to long-term trastuzumab therapy in metastatic breast cancer: the potential role of treatment duration and cardiac risk factors.

The breast journal 2015 May-Jun;21;318-21 — 2015 May-Jun — 318-21

Ayres LR, de Almeida Campos MS, de Oliveira Gozzo T, Martinez EZ, Ungari AQ, de Andrade JM, Pereira LR

Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital.

International journal of clinical pharmacy 2015 Apr;37;365-72 — 2015 Apr — 365-72

Farolfi A, Melegari E, Aquilina M, Scarpi E, Ibrahim T, Maltoni R, Sarti S, Cecconetto L, Pietri E, Ferrario C, Fedeli A, Faedi M, Nanni O, Frassineti GL, Amadori D, Rocca A

Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.

Heart (British Cardiac Society) 2013 May;99;634-9 — 2013 May — 634-9

Fedele C, Riccio G, Coppola C, Barbieri A, Monti MG, Arra C, Tocchetti CG, D'Alessio G, Maurea N, De Lorenzo C

Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors.

Breast cancer research and treatment 2012 Jun;133;511-21 — 2012 Jun — 511-21

Guglin M, Hartlage G, Reynolds C, Chen R, Patel V

Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study.

Journal of cardiac failure 2009 Oct;15;651-7 — 2009 Oct — 651-7